Search research articles
Contact Us
Filters
Showing results (51-60 of 56) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 56 results.
Frontiers in Microbiology
|
January 23, 2023
Structure and metabolic potential of the prokaryotic communities from the hydrothermal system of Paleochori Bay, Milos, Greece
Sven Le Moine Bauer, Guang-Sin Lu, Steven Goulaouic, et al.
The Lancet. HIV
|
September 24, 2016
Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial
Steffen Leth, Mariane H Schleimann, Sara K Nissen, et al.
Plos Pathogens
|
September 18, 2015
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
Ole S Søgaard, Mette E Graversen, Steffen Leth, et al.
Clinical and Experimental Immunology
|
April 10, 2026
Immunological Dysfunction Associated with SARS-CoV-2 Persistence in Immunocompromised Patients
Ida M Johannsen, Line K Vibholm, Giacomo S Frattari, et al.
Clinical Epidemiology
|
June 12, 2026
The Danish Database for Hepatitis B and C (DANHEP): A Nationwide, Prospective, Ongoing Cohort Study
Signe Bollerup, Christina Sølund, Sofie Hallager, et al.
Nature Medicine
|
September 11, 2023
Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial
Jesper D Gunst, Jesper F Højen, Marie H Pahus, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 56) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 56 results.
Frontiers in Microbiology
|
January 23, 2023
Structure and metabolic potential of the prokaryotic communities from the hydrothermal system of Paleochori Bay, Milos, Greece
Sven Le Moine Bauer, Guang-Sin Lu, Steven Goulaouic, et al.
The Lancet. HIV
|
September 24, 2016
Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial
Steffen Leth, Mariane H Schleimann, Sara K Nissen, et al.
Plos Pathogens
|
September 18, 2015
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
Ole S Søgaard, Mette E Graversen, Steffen Leth, et al.
Clinical and Experimental Immunology
|
April 10, 2026
Immunological Dysfunction Associated with SARS-CoV-2 Persistence in Immunocompromised Patients
Ida M Johannsen, Line K Vibholm, Giacomo S Frattari, et al.
Clinical Epidemiology
|
June 12, 2026
The Danish Database for Hepatitis B and C (DANHEP): A Nationwide, Prospective, Ongoing Cohort Study
Signe Bollerup, Christina Sølund, Sofie Hallager, et al.
Nature Medicine
|
September 11, 2023
Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial
Jesper D Gunst, Jesper F Højen, Marie H Pahus, et al.
Page
of 6